The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia

European Urology

Volumn 63, Issue 3, 2013, Pages 506-516

  Giuliano, François ^a   Ückert, Stefan ^b,c   Maggi, Mario ^d   Birder, Lori ^e   Kissel, Jay ^f   Viktrup, Lars ^f  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Institute for Biochemical Research and Analysis   (Germany)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Mechanism of action; Phosphodiesterase type 5; Phosphodiesterase type 5 inhibitors

Indexed keywords

GISADENAFIL; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; VARDENAFIL;

BLADDER; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; LOWER URINARY TRACT SYMPTOM; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSORY NERVE; SMOOTH MUSCLE RELAXATION; SYSTEMATIC REVIEW; URETHRA;

EVIDENCE-BASED MEDICINE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATE; PROSTATIC HYPERPLASIA; URINARY BLADDER;

EID: 84872940957     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.09.006     Document Type: Review

References (70)

1. C.J. Fowler, D. Griffiths, and W.C. de Groat The neural control of micturition Nat Rev Neurosci 9 2008 453 466 (Pubitemid 351704950)
2. C.G. Roehrborn Pathology of benign prostatic hyperplasia Int J Impot Res 20 Suppl 3 2008 S11 S18
3. K.E. Andersson, W.C. de Groat, and K.T. McVary Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action Neurourol Urodyn 30 2011 292 301
4. M. Gacci, I. Eardley, and F. Giuliano Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 60 2011 809 825
5. R.B. Egerdie, S. Auerbach, and C.G. Roehrborn Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study J Sex Med 9 2012 271 281
6. K.T. McVary, C.G. Roehrborn, and J.C. Kaminetsky Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 2007 1401 1407 (Pubitemid 46435965)
7. M. Oelke, F. Giuliano, V. Mirone, L. Xu, D. Cox, and L. Viktrup Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial Eur Urol 61 2012 917 925
8. H. Porst, E.D. Kim, and A.R. Casabé Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial Eur Urol 60 2011 1105 1113
9. C.G. Roehrborn, K.T. McVary, A. Elion-Mboussa, and L. Viktrup Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228 1234
10. V. Mirone, A. Sessa, F. Giuliano, R. Berges, M. Kirby, and I. Moncada Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events Int J Clin Pract 65 2011 1005 1013
11. American Urological Association guideline: management of benign prostatic hyperplasia (BPH). American Urological Association Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines. cfm. Accessed November 2011.
12. N.A. Tamimi, I. Mincik, S. Haughie, J. Lamb, A. Crossland, and P. Ellis A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia BJU Int 106 2010 674 680
13. K.T. McVary, W. Monnig, J.L. Camps Jr., J.M. Young, L.J. Tseng, and G. van den Ende Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 2007 1071 1077 (Pubitemid 46216352)
14. C.G. Stief, H. Porst, D. Neuser, M. Beneke, and E. Ulbrich A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
15. M. Gacci, G. Corona, and M. Salvi A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia Eur Urol 61 2012 994 1003
16. H.K. Laydner, P. Oliveira, and C.R. Oliveira Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review BJU Int 107 2011 1104 1109
17. J.I. Martínez-Salamanca, J. Carballido, and I. Eardley Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence Eur Urol 60 2011 527 535
18. L. Liu, S. Zheng, P. Han, and Q. Wei Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis Urology 77 2011 123 129
19. C.F. Donatucci, G.B. Brock, and E.R. Goldfischer Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study BJU Int 107 2011 1110 1116
20. R.S. Kirby, and J.L. Pool Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future Br J Urol 80 1997 521 532 (Pubitemid 28316371)
21. R. Kuciel, and W. Ostrowski Phosphodiesterase from human prostate gland Bull Soc Chim Biol (Paris) 52 1970 1051 1060
22. S. Uckert, A. Kuthe, U. Jonas, and C.G. Stief Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate J Urol 166 2001 2484 2490 (Pubitemid 33065340)
23. S. Uckert, M. Sormes, and G. Kedia Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue Urology 71 2008 526 530 (Pubitemid 351374723)
24. R. Dmochowski, C. Roehrborn, S. Klise, L. Xu, J. Kaminetsky, and S. Kraus Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial J Urol 183 2010 1092 1097
25. G.A. Broderick, G.B. Brock, C.G. Roehrborn, S.D. Watts, A. Elion-Mboussa, and L. Viktrup Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction Urology 75 2010 1452 1458
26. M.C. Truss, S. Uckert, C.G. Stief, M. Kuczyk, and U. Jonas Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization Urol Res 24 1996 123 128 (Pubitemid 26226247)
27. S. Filippi, A. Morelli, and P. Sandner Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 2007 1019 1029
28. S. Uckert, P. Sandner, K. Sigl, E. Ulbrich, C. Stief, and M. Kuczyk Is there a role of the phosphodiesterase type 5 (PDE5) in the control of detrusor smooth muscle? A functional and molecular biology study J Urol 181 2009 152
29. B. Fibbi, A. Morelli, and L. Vignozzi Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract J Sex Med 7 2010 59 69
30. P. Hedlund Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract - is there a basis for pharmacological targeting of cGMP? World J Urol 23 2005 362 367 (Pubitemid 43124386)
31. G.T. Kedia, S. Uckert, U. Jonas, M.A. Kuczyk, and M. Burchardt The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms World J Urol 26 2008 603 609
32. S. Uckert, E.S. Waldkirch, M.A. Kuczyk, and P. Hedlund Phosphodiesterase type 5 is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate Eur Urol Suppl 10 2011 182
33. V. Werkstrom, A. Svensson, K.E. Andersson, and P. Hedlund Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects BJU Int 98 2006 414 423
34. G. Kedia, M. Kuczyk, P. Hedlund, and S. Uckert Expression and distribution of phosphodiesterase (PDE) isoenzymes in the human urethra J Urol 185 2011 e91
35. S. Oger, D. Behr-Roussel, and D. Gorny Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle Br J Pharmacol 160 2010 1135 1143
36. J.A. Bittencourt, T. Tano, and S.A. Gajar Relaxant effects of sildenafil on the human isolated bladder neck Urology 73 2009 427 430
37. A. Morelli, E. Sarchielli, and P. Comeglio Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats J Sex Med 8 2011 2746 2760
38. G.T. Kedia, S. Uckert, M. Kedia, and M.A. Kuczyk Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue Urology 73 2009 1397 1401
39. S. Uckert, H. Polat-Yurur, F. Scheller, G. Kedia, and M. Kuczyk Stimulation of cyclic nucleotide production enhances the relaxation induced by phosphodiesterase (PDE) inhibitors of isolated human prostate tissue J Urol 181 2009 507
40. K.M. Ho, G. McMurray, A.F. Brading, J.G. Noble, L. Ny, and K.E. Andersson Nitric oxide synthase in the heterogeneous population of intramural striated muscle fibres of the human membranous urethral sphincter J Urol 159 1998 1091 1096 (Pubitemid 28106599)
41. G.T. Kedia, J.E. Sonnenberg, M.A. Kuczyk, and S. Uckert In vitro functional responses of isolated human urethral tissue to phosphodiesterase (PDE) inhibitors Eur Urol Suppl 10 2011 291 292
42. J.G. Lee, G. Moon du, S.H. Kang, D.Y. Cho, H.S. Park, and J.H. Bae Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra: in vitro and in vivo study Urol Int 84 2010 231 235
43. B. von Heyden, U. Jordan, W. Schmitz, and L. Hertle Urethral relaxation after electrostimulation in the guinea pig is independent of nitric oxide J Urol 157 1997 1509 1513 (Pubitemid 27130861)
44. S. Moul, and K.T. McVary Lower urinary tract symptoms, obesity and the metabolic syndrome Curr Opin Urol 20 2010 7 12
45. A. Morelli, S. Filippi, and P. Comeglio Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats J Sex Med 7 2010 107 120
46. K.M. Azadzoi, R.K. Babayan, R. Kozlowski, and M.B. Siroky Chronic ischemia increases prostatic smooth muscle contraction in the rabbit J Urol 170 2003 659 663 (Pubitemid 36870279)
47. L. Vignozzi, A. Morelli, and E. Sarchielli Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit J Endocrinol 212 2012 71 84
48. A. Morelli, P. Comeglio, and S. Filippi Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome J Steroid Biochem Mol Biol 132 2012 80 92
49. E.J. Clegg The arterial supply of the human prostate and seminal vesicles J Anat 89 1955 209 216
50. M. Yono, Y. Yamamoto, M. Yoshida, S. Ueda, and J. Latifpour Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract Life Sci 81 2007 218 222 (Pubitemid 46976980)
51. M. Bertolotto, E. Trincia, R. Zappetti, R. Bernich, G. Savoca, and M.A. Cova Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US Radiol Med 114 2009 1106 1114
52. J.I. Gillespie, M. Markerink-van Ittersum, and J. de Vente Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder Cell Tissue Res 321 2005 341 351 (Pubitemid 41206988)
53. J.I. Gillespie, M. Markerink-van Ittersum, and J. De Vente Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: evidence for distinct populations of sub-urothelial interstitial cells Cell Tissue Res 325 2006 325 332 (Pubitemid 44050798)
54. I. Ehren, H. Iversen, O. Jansson, J. Adolfsson, and N.P. Wiklund Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses Urology 44 1994 683 687
55. G.P. Sui, S. Rothery, E. Dupont, C.H. Fry, and N.J. Severs Gap junctions and connexin expression in human suburothelial interstitial cells BJU Int 90 2002 118 129
56. Y. Ikeda, C. Fry, F. Hayashi, D. Stolz, D. Griffiths, and A. Kanai Role of gap junctions in spontaneous activity of the rat bladder Am J Physiol Renal Physiol 293 2007 F1018 F1025
57. C.J. McCarthy, I.V. Zabbarova, P.R. Brumovsky, J.R. Roppolo, G.F. Gebhart, and A.J. Kanai Spontaneous contractions evoke afferent nerve firing in mouse bladders with detrusor overactivity J Urol 181 2009 1459 1466
58. L.A. Birder, G. Apodaca, W.C. De Groat, and A.J. Kanai Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder Am J Physiol 275 1998 F226 F229
59. L.A. Birder, M.L. Nealen, and S. Kiss Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells J Neurosci 22 2002 8063 8070 (Pubitemid 35379112)
60. A. Sculptoreanu, and W.C. de Groat Neurokinins enhance excitability in capsaicin-responsive DRG neurons Exp Neurol 205 2007 92 100 (Pubitemid 46617494)
61. N. Yoshimura, S. Seki, and W.C. de Groat Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder J Neurophysiol 86 2001 304 311 (Pubitemid 32623235)
62. K. Persson, Y. Igawa, A. Mattiasson, and K.E. Andersson Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro Br J Pharmacol 107 1992 178 184
63. F.Z. Monica, A.A. Bricola, and F.R. Bau Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity Br J Pharmacol 153 2008 1659 1668 (Pubitemid 351545807)
64. R.K. Pandita, H. Mizusawa, and K.E. Andersson Intravesical oxyhemoglobin initiates bladder overactivity in conscious, normal rats J Urol 164 2000 545 550 (Pubitemid 30481981)
65. R. Caremel, S. Oger-Roussel, D. Behr-Roussel, P. Grise, and F.A. Giuliano Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat Eur Urol 58 2010 616 625
66. T. Minigawa, N. Aizawa, Y. Igawa, and J.J. Wyndaele Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves BJU Int 110 2012 E259 E266
67. W.C. de Groat, and N. Yoshimura Changes in afferent activity after spinal cord injury Neurourol Urodyn 29 2010 63 76
68. K. Iijima, Y. Igawa, J.J. Wyndaele, and S. De Wachter Mechanosensitive primary bladder afferent activity in rats with and without spinal cord transection J Urol 182 2009 2504 2510
69. D. Behr-Roussel, S. Oger, and S. Caisey Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats Eur Urol 59 2011 272 279
70. K. Sasatomi, S. Hiragata, M. Miyazato, M.B. Chancellor, S.M. Morris Jr., and N. Yoshimura Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury Urology 72 2008 696 700